LEWA signs global license deal

As a result of the agreement with ChromaCon in the field of continuous downstream processing, the biopharmaceutical industry can expect significant cost savings and quality benefits.

Have a Question?

 
1 Start 2 Complete

Get prompt answers to questions about our products and services.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.